Redcare Pharmacy NV (ETR:RDC)
| Market Cap | 910.65M -64.2% |
| Revenue (ttm) | 3.07B +21.6% |
| Net Income | -37.40M |
| EPS | n/a |
| Shares Out | 20.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,596 |
| Average Volume | 122,783 |
| Open | 45.20 |
| Previous Close | 44.58 |
| Day's Range | 45.02 - 45.52 |
| 52-Week Range | 30.20 - 130.10 |
| Beta | 1.45 |
| RSI | 47.11 |
| Earnings Date | May 6, 2026 |
About Redcare Pharmacy NV
Redcare Pharmacy NV operates the online pharmacy business in the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France. It offers prescription and non-prescription over-the-counter pharmaceuticals, beauty and personal care products, and food supplements. The company was formerly known as Shop Apotheke Europe N.V. and changed its name to Redcare Pharmacy NV in June 2023. Redcare Pharmacy NV was founded in 2001 and is based in Sevenum, the Netherlands. [Read more]
Financial Performance
In 2025, Redcare Pharmacy NV's revenue was 2.94 billion, an increase of 24.06% compared to the previous year's 2.37 billion. Losses were -37.70 million, -17.14% less than in 2024.
Financial StatementsNews
Redcare Pharmacy NV Earnings Call Transcript: Q1 2026
Q1 2026 saw 18% revenue growth to €849M, with strong Rx and non-Rx performance, improved EBITDA margin, and a rebound in German non-Rx. Guidance remains unchanged amid regulatory uncertainty and early-year volatility, with continued investment in IT and marketing optimization.
Redcare Pharmacy NV Slides: Q1 2026
Redcare Pharmacy NV has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Redcare Pharmacy NV Quarterly report: Q1 2026
Redcare Pharmacy NV has published its Q1 2026 quarterly earnings report on May 6, 2026.
Redcare Pharmacy NV Earnings release: Q1 2026
Redcare Pharmacy NV released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Redcare Pharmacy NV Earnings Call Transcript: Q1 2026
Q1 2026 saw 18% revenue growth to €849M, with strong Rx and non-Rx performance, improved EBITDA margin, and a rebound in German non-Rx. Guidance remains unchanged amid regulatory uncertainty and early-year volatility, with continued investment in IT and marketing optimization.
Redcare Pharmacy NV Slides: Q1 2026
Redcare Pharmacy NV has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Redcare Pharmacy NV Quarterly report: Q1 2026
Redcare Pharmacy NV has published its Q1 2026 quarterly earnings report on May 6, 2026.
Redcare Pharmacy NV Earnings release: Q1 2026
Redcare Pharmacy NV released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Redcare Pharmacy NV Earnings Call Transcript: Q1 2026
Q1 2026 saw 18% revenue growth to €849M, with strong Rx and non-Rx performance, improved EBITDA margin, and a rebound in German non-Rx. Guidance remains unchanged amid regulatory uncertainty and early-year volatility, with continued investment in IT and marketing optimization.
Redcare Pharmacy NV Slides: Q1 2026
Redcare Pharmacy NV has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Redcare Pharmacy NV Quarterly report: Q1 2026
Redcare Pharmacy NV has published its Q1 2026 quarterly earnings report on May 6, 2026.
Redcare Pharmacy NV Earnings release: Q1 2026
Redcare Pharmacy NV released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Redcare Pharmacy NV Earnings Call Transcript: Q4 2025
Full-year revenues rose 24% to EUR 2.9 billion, driven by strong Rx growth and logistics expansion. 2026 guidance targets 13%-15% sales growth, Rx Germany revenues above EUR 670 million, and an adjusted EBITDA margin of at least 2.5%.
Redcare Pharmacy NV Earnings release: Q4 2025
Redcare Pharmacy NV released its Q4 2025 earnings on March 4, 2026, summarizing the period's financial results.
Redcare Pharmacy NV Annual report: Q4 2025
Redcare Pharmacy NV has published its Q4 2025 annual report on March 4, 2026.
Redcare Pharmacy NV Slides: Q4 2025
Redcare Pharmacy NV has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 4, 2026.
Redcare Pharmacy NV Earnings Call Transcript: Q4 2025
Full-year revenues rose 24% to EUR 2.9 billion, driven by strong Rx growth and logistics expansion. 2026 guidance targets 13%-15% sales growth, Rx Germany revenues above EUR 670 million, and an adjusted EBITDA margin of at least 2.5%.
Redcare Pharmacy NV Earnings release: Q4 2025
Redcare Pharmacy NV released its Q4 2025 earnings on March 4, 2026, summarizing the period's financial results.
Redcare Pharmacy NV Annual report: Q4 2025
Redcare Pharmacy NV has published its Q4 2025 annual report on March 4, 2026.
Redcare Pharmacy NV Slides: Q4 2025
Redcare Pharmacy NV has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 4, 2026.
Redcare Pharmacy NV Earnings Call Transcript: Q4 2025
Full-year revenues rose 24% to EUR 2.9 billion, driven by strong Rx growth and logistics expansion. 2026 guidance targets 13%-15% sales growth, Rx Germany revenues above EUR 670 million, and an adjusted EBITDA margin of at least 2.5%.
Redcare Pharmacy NV Earnings release: Q4 2025
Redcare Pharmacy NV released its Q4 2025 earnings on March 4, 2026, summarizing the period's financial results.
Redcare Pharmacy NV Annual report: Q4 2025
Redcare Pharmacy NV has published its Q4 2025 annual report on March 4, 2026.
Redcare Pharmacy NV Slides: Q4 2025
Redcare Pharmacy NV has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 4, 2026.
German online drug retailer Redcare Pharmacy names Hendrik Krampe as CFO
German online drug retailer Redcare Pharmacy on Monday named Hendrik Krampe as its chief financial officer, effective December 1.